Cite
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial.
MLA
Voors, Adriaan A., et al. “Effects of Danicamtiv, a Novel Cardiac Myosin Activator, in Heart Failure with Reduced Ejection Fraction: Experimental Data and Clinical Results from a Phase 2a Trial.” European Journal of Heart Failure, vol. 22, no. 9, Sept. 2020, pp. 1649–58. EBSCOhost, https://doi.org/10.1002/ejhf.1933.
APA
Voors, A. A., Tamby, J.-F., Cleland, J. G., Koren, M., Forgosh, L. B., Gupta, D., Lund, L. H., Camacho, A., Karra, R., Swart, H. P., Pellicori, P., Wagner, F., Hershberger, R. E., Prasad, N., Anderson, R., Anto, A., Bell, K., Edelberg, J. M., Fang, L., … Solomon, S. D. (2020). Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. European Journal of Heart Failure, 22(9), 1649–1658. https://doi.org/10.1002/ejhf.1933
Chicago
Voors, Adriaan A, Jean-François Tamby, John G Cleland, Michael Koren, Leslie B Forgosh, Dinesh Gupta, Lars H Lund, et al. 2020. “Effects of Danicamtiv, a Novel Cardiac Myosin Activator, in Heart Failure with Reduced Ejection Fraction: Experimental Data and Clinical Results from a Phase 2a Trial.” European Journal of Heart Failure 22 (9): 1649–58. doi:10.1002/ejhf.1933.